文献速递艾滋病与性传播感染

HIV感染者从利托那韦增强PI换用拉替拉韦或多替拉韦后胰岛素敏感性与血清瘦素改善

Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

一项观察性前瞻性队列研究纳入86例接受稳定cART的非糖尿病HIV感染者,换用拉替拉韦或多替拉韦后随访12个月。两组瘦素、胰岛素及HOMA指数均显著下降,组间无显著差异,提示胰岛素敏感性改善。

要点

  • 换用拉替拉韦或多替拉韦后12个月HOMA指数和瘦素均显著下降
  • 两组胰岛素敏感性改善程度相似且无显著组间差异
  • 换药同时观察到血脂水平显著下降

核心结论

  • 在病毒抑制的HIV感染者中,从PI/r换用拉替拉韦或多替拉韦可显著且相当地降低HOMA指数和血清瘦素,反映胰岛素敏感性改善。

研究设计与样本

  • 观察性前瞻性队列研究,纳入86例非糖尿病HIV感染者,均接受替诺福韦二吡呋酯/恩曲他滨联合一种PI/r的抑制性cART。
  • 换药后分为拉替拉韦组(A组,45例)和多替拉韦组(B组,41例),随访12个月。
  • 平均年龄45.7岁,男性74例(86%)。

主要发现

  • A组瘦素平均下降0.61 ng/mL(P < 0.001),胰岛素平均下降2.5 mIU/L(P = 0.008)。
  • B组瘦素平均下降0.54 ng/mL(P = 0.005),胰岛素平均下降2.1 mIU/L(P = 0.017)。
  • 两组间瘦素和胰岛素变化无显著差异。
  • A组HOMA指数平均下降0.55(P = 0.004),B组平均下降0.49(P < 0.001)。
  • 两组血脂水平均显著下降。

临床怎么用

  • 对于接受含PI/r方案且病毒抑制的非糖尿病HIV感染者,换用拉替拉韦或多替拉韦可能改善胰岛素敏感性和血脂。
  • 换药决策需综合病毒学抑制、耐受性和合并用药等因素个体化评估。

局限性

  • 观察性研究设计,非随机分组,可能存在选择偏倚和混杂因素。
  • 样本量较小(共86例),随访时间12个月,长期影响未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: An observational, prospective, cohort study was performed to assess changes in insulin sensitivity and serum leptin level after a switch from a ritonavir-boosted PI (PI/r) to raltegravir or dolutegravir in HIV-infected adults on stable combination ART (cART). METHODS: Non-diabetic HIV-infected patients receiving suppressive cART including tenofovir disoproxil fumarate/emtricitabine plus one PI/r, who underwent a switch from the PI/r to raltegravir (group A) or dolutegravir (group B), were enrolled in the study. Serum levels of insulin, leptin and the homeostasis model assessment of insulin resistance (HOMA) index were evaluated during a 12 month follow-up. RESULTS: Overall, 86 patients were enrolled: 45 patients were included in group A and 41 were included in group B. The mean age was 45.7 years and 74 (86%) patients were male. After 12 months of follow-up, a significant reduction in the mean concentration of leptin and insulin was reported both in group A [-0.61 ng/mL (P < 0.001) and -2.5 mIU/L (P = 0.008), respectively] and in group B [-0.54 ng/mL (P = 0.005) and -2.1 mIU/L (P = 0.017), respectively], without a significant difference between the groups. A significant and comparable reduction in the mean HOMA index was reported both in group A [-0.55 (P = 0.004)] and in group B [-0.49 (P < 0.001)], as well as a significant decrease in lipid levels. CONCLUSIONS: In HIV-positive subjects on suppressive cART, the switch from a PI/r to raltegravir or dolutegravir led to a significant and comparable reduction in both HOMA index and serum leptin level, reflecting a similar and significant improvement in insulin sensitivity.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Calza L, Colangeli V, Borderi M, et al. Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients. J Antimicrob Chemother. 2019. PMID: 30541118. doi:10.1093/jac/dky507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。